Matthew McManus compensation by year
BIO-TECHNE Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $253,846 | $572,000 |
| Bonus | $0 | $0 |
| Stock awards | $1,081,995 | $1,213,200 |
| Option awards | $527,793 | $596,695 |
| Non-equity incentive | $124,027 | $444,787 |
| Pension and deferred compensation | $0 | $0 |
| All other | $6,980 | $19,937 |
| Total | $1,994,642 | $2,846,619 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIO-TECHNE Corp DEF 14A filed September 19, 2025, accession 0001308179-25-000599, and prior-year filings. Open the filing on EDGAR.
How this page was built: the BIO-TECHNE Corp filed document, accession 0001308179-25-000599. Every figure is read from that document and cited to the page and table it appears in. Filed September 19, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 13,861 | $993,141 | — |
| PSU | 2,888 | $206,925 | — |
| Option | 15,902 | — | $68.54 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIO-TECHNE Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed September 19, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-02-01 | Exercise or conversion | — | 4,621 | $0.00 | 9,356 |
| 2026-02-01 | Exercise or conversion derivative | — | 4,621 | $0.00 | 4,620 |
| 2026-02-01 | Tax withholding | — | 1,665 | $64.09 | 7,691 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
BIO-TECHNE’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kim Kelderman | President and CEO | $8,151,181 |
| James Hippel | Executive Vice President and CFO | $7,027,382 |
| William Geist | President, Protein Sciences | $3,139,299 |
| Matthew McManus · this page | President, Diagnostics and Spatial Biology | $2,846,619 |
| Shane Bohnen | Senior Vice President and General Counsel | $1,980,732 |
Matthew McManus's compensation dossier, BIO-TECHNE
You have read Matthew McManus's totals and holdings. The dossier adds each equity grant BIO-TECHNE disclosed for Matthew McManus and BIO-TECHNE's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full BIO-TECHNE compensation record
free company briefThis page is one person within BIO-TECHNE's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BIO-TECHNE proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIO-TECHNE's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIO-TECHNE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TECH
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.